We have had a rough few weeks for biotech companies; however, the majority of biotechs are very healthy in every aspect—sales and earnings, clinical trials, R&D, and cash positions—explains John McCamant, editor of The Medical Technology Stock Letter.
The numerous breakthroughs occurring to treat various potentially fatal conditions—increasing survival and quality of life—have continued at a historical pace. Investors should take advantage when fear is being reflected in stock prices.
Incyte (INCY) delivered the goods—and then some—at the recent AACR meeting where the company presented eleven abstracts detailing its emerging small molecule cancer drug development pipeline.
The abstracts included characterizations of potential therapies for cancer, as well as data supporting the potential immuno-therapeutic activity of its portfolio of inhibitors.
In our view, Incyte has become the leading developer of small molecule cancer drugs with an industry-leading pipeline that is second to none.
Incyte is poised to start a very aggressive clinical development program with four different proof-of-concept combo trials that are expected to start in the second half of the year.
Epacadostat, in our view, is the crown jewel in Incyte's outstanding cancer pipeline. This drug candidate is oral and safe, making it the ideal combo drug where safety is paramount.
Combo therapy of cancer drugs is the key to immuno-oncology as the second and third drugs synergize the treatment paradigm by not just killing tumors but also reprogramming the immune system, which allows for cancer surveillance and prevention.
We believe INCY's small molecule cancer pipeline has the best potential for creating the three+ drug combos that are expected to dominate the immuno-oncology cancer treatment space, making Incyte the most attractive cancer company in our universe.
We also believe Incyte is a possible takeover target; their pipeline alone would be transformative for any big pharma or biotech company. In our view, INCY is a strategy acquisition that could propel a cancer laggard to the top of the class.
Subscribe to The Medical Technology Stock Letter here…
More from MoneyShow.com:
